Part 7/10:
A significant part of the discussion revolves around pioneering health technologies, such as the development of "bioshield" or "bioshock"—a concept of harnessing the body's immune system to combat infections and cancer without relying on traditional chemo or radiation therapies. The speaker reminisces about a long-term project involving a breakthrough in natural killer cell therapies, which showed promise in fighting tumors.
However, frustration arises with regulatory agencies like the FDA, perceived as bureaucratic and resistant to evolving science. Despite the potential of these treatments, bureaucratic inertia hampers progress, highlighting the disconnect between scientific innovation and regulatory approval processes.